NextCell Pharma AB (FRA:65G)
Germany · Delayed Price · Currency is EUR 0.0554
+0.0092 (19.91%)
Last updated: Dec 1, 2025, 8:11 AM CET
NextCell Pharma AB Balance Sheet
Financials in millions SEK. Fiscal year is September - August.
Millions SEK. Fiscal year is Sep - Aug.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 38.72 | 46.79 | 50.03 | 97.12 | 139.17 | Upgrade |
Cash & Short-Term Investments | 38.72 | 46.79 | 50.03 | 97.12 | 139.17 | Upgrade |
Cash Growth | -17.24% | -6.47% | -48.49% | -30.22% | 533.78% | Upgrade |
Accounts Receivable | 3 | 1.67 | 2.35 | 1.78 | 1.39 | Upgrade |
Other Receivables | 1.98 | 1.45 | 1.24 | 0.93 | 0.31 | Upgrade |
Receivables | 4.98 | 3.12 | 3.58 | 2.71 | 1.7 | Upgrade |
Inventory | 0.55 | 0.55 | 0.79 | 0.77 | - | Upgrade |
Prepaid Expenses | 10.15 | 10.17 | 12.87 | 6.16 | 5.61 | Upgrade |
Other Current Assets | - | 0.05 | 0 | - | - | Upgrade |
Total Current Assets | 54.4 | 60.67 | 67.27 | 106.75 | 146.48 | Upgrade |
Property, Plant & Equipment | 14.33 | 12.66 | 13.55 | 9.9 | 2.9 | Upgrade |
Long-Term Investments | 6.87 | 6.92 | 6.87 | 6.87 | 5.11 | Upgrade |
Other Long-Term Assets | 1.14 | 1.03 | 1.13 | 1.13 | 1.13 | Upgrade |
Total Assets | 76.73 | 81.29 | 88.83 | 124.66 | 155.63 | Upgrade |
Accounts Payable | 2.69 | 6.16 | 0.89 | 1.92 | 1.28 | Upgrade |
Accrued Expenses | 2.25 | 2.49 | 7.65 | 4.16 | 0.59 | Upgrade |
Current Unearned Revenue | - | 0.25 | 0.2 | - | - | Upgrade |
Other Current Liabilities | 0.49 | 0.98 | 1.35 | 0.85 | 2.08 | Upgrade |
Total Current Liabilities | 5.43 | 9.87 | 10.08 | 6.93 | 3.96 | Upgrade |
Long-Term Unearned Revenue | 4.92 | 3.82 | 3.02 | 2.18 | 1.58 | Upgrade |
Other Long-Term Liabilities | -0 | -0 | -0 | - | - | Upgrade |
Total Liabilities | 10.34 | 13.69 | 13.1 | 9.12 | 5.53 | Upgrade |
Common Stock | 22.84 | 14.98 | 7.05 | 7.05 | 7.05 | Upgrade |
Additional Paid-In Capital | 248.41 | 222.33 | 196.43 | 196.43 | 196.43 | Upgrade |
Retained Earnings | -204.85 | -169.71 | -127.75 | -87.94 | -53.38 | Upgrade |
Shareholders' Equity | 66.39 | 67.6 | 75.73 | 115.54 | 150.09 | Upgrade |
Total Liabilities & Equity | 76.73 | 81.29 | 88.83 | 124.66 | 155.63 | Upgrade |
Net Cash (Debt) | 38.72 | 46.79 | 50.03 | 97.12 | 139.17 | Upgrade |
Net Cash Growth | -17.24% | -6.47% | -48.49% | -30.22% | 533.78% | Upgrade |
Net Cash Per Share | 0.51 | 1.15 | 1.46 | 2.82 | 4.58 | Upgrade |
Filing Date Shares Outstanding | 111.39 | 73.09 | 34.38 | 34.38 | 34.38 | Upgrade |
Total Common Shares Outstanding | 111.39 | 73.09 | 34.38 | 34.38 | 34.38 | Upgrade |
Working Capital | 48.97 | 50.8 | 57.19 | 99.82 | 142.52 | Upgrade |
Book Value Per Share | 0.60 | 0.92 | 2.20 | 3.36 | 4.37 | Upgrade |
Tangible Book Value | 66.39 | 67.6 | 75.73 | 115.54 | 150.09 | Upgrade |
Tangible Book Value Per Share | 0.60 | 0.92 | 2.20 | 3.36 | 4.37 | Upgrade |
Machinery | - | 16.04 | 5.22 | 5.15 | 5.25 | Upgrade |
Construction In Progress | - | - | 11.59 | 7.56 | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.